Update on overall survival (OS) of RESCUE: An open-label, phase 2 trial of camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (HCC).

Authors

null

Yun Zhang

The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China

Yun Zhang , Jianming Xu , Jie Shen , Shanzhi Gu , Lihua Wu , Jian Wu , Guoliang Shao , Yanqiao Zhang , Li Xu , Tao Yin , Jingfeng Liu , Zhenggang Ren , Jianping Xiong , Xianhai Mao , Ling Zhang , Jiayin Yang , Lequn Li , Xiaoming Chen , Zhiming Wang , Quanren Wang

Organizations

The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, Hunan Cancer Hospital, Changsha, China, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China, Zhejiang Cancer Hospital, Hangzhou, China, Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China, Sun Yat-sen University Cancer Center, Guangzhou, China, Hubei Cancer Hospital, Affiliated Hubei Cancer Hospital of Huazhong University of Science and Technology, Wuhan, China, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China, Zhongshan Hospital, Fudan University, Shanghai, China, The First Affiliated Hospital of Nanchang University, Nanchang, China, Hunan People's Hospital, Changsha, China, Henan Cancer Hospital, Zhengzhou, China, West China Hospital of Sichuan University, Chengdu, China, Guangxi Medical University Affiliated Tumor Hospital, Nanning, China, Guangdong Provincial People's Hospital, Guangzhou, China, Xiangya Hospital Central South University, Changsha, China, Jiangsu Hengrui Medicine Co., Ltd., Shanghai, China

Research Funding

Pharmaceutical/Biotech Company
Jiangsu Hengrui Medicine Co., Ltd

Background: C+A combination therapy displayed high objective response rate, disease control rate, and durable response with a manageable safety profile in patients (pts) with advanced HCC. Here we performed an updated analysis of OS to characterize the OS benefit of C+A in HCC pts. Methods: 70 pts in first-line cohort and 120 pts in second-line cohort were enrolled. Median OS and 2-year OS rate were evaluated via updated data (data cutoff, 3 January, 2021). Median time from enrollment to data cutoff of the total population (N = 190) was 29.1 months (range, 24.0-33.7). Results: OS events had occurred in 58.6% pts in first-line cohort and 60.0% pts in second-line cohort. The median OS was 20.1 months (95% CI, 14.9-NR) and 2-year OS rate was 43.3% (95% CI, 31.3-54.7) in first-line cohort. The median OS was 21.8 months (95% CI, 17.3-26.8) and 2-year OS rate was 44.6% (95% CI, 35.5-53.3) in second-line cohort. Conclusions: Long-term follow-up of C+A demonstrated remarkable survival benefit in advanced HCC pts, which further suggested that C+A is a promising combination therapy in advanced HCC pts. Clinical trial information: NCT03463876

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT03463876

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4076)

DOI

10.1200/JCO.2021.39.15_suppl.4076

Abstract #

4076

Poster Bd #

Online Only

Abstract Disclosures